HEPALINA HEPA MERZ HEPA MERZ HEPA MERZ HEPA MERZ HEPA MERZ HEPALEX HEPALEX HEPATONE HEPATONE LOTASS LOTASS LOTASS MULTINA MAX MULTINA MAX MULTINA MAX ORNAMIN ENERVIN HEPA SPARTATE EPURAM EPURAM EPURAM EPURAM AMINO ACID SIOVENA LEVIJON LEVIJON LEVIJON AMINOPLASMAL-L10 AKSOHEP ORNIVIT LOSANTA LOSANTA KOSAAR ACTI-TONE REVERZ GLUTAN ORNITATE ORNITATE MERZEPA MERZEPA MAXART-25 MAXART TABLET MAXART PLUS L-TAN ROSAR-H

Dose: 300 mg
Single Dose: 300 (300)
Frequency: 12 hourly
Route: IV
Instructions: For 3-4 Weeks

It belongs to Hepatoprotective, Lipotropic pharmacological group.

L-Ornithine L-Aspartate is contraindicated in conditions like Pregnancy,Renal insufficiency.

The symptomatic adverse reactions produced by L-Ornithine L-Aspartate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Transient nausea and vomiting.

L-Ornithine L-Aspartate is primarily indicated in conditions like Hepatic encephalopathy, Hepatitis, Jaundice, Liver cirrhosis, and can also be given in adjunctive therapy as an alternative drug of choice in Tuberculosis.

No data regarding the interactions of L-Ornithine L-Aspartate was found.

Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

In patient with severe renal insufficiency blood urea, and serum creatinine must be monitored regularly, serum creartinine value exceeding 3gm/ml is regarded as reference value.